Critical Contrast: CureVac (CVAC) & Its Competitors

CureVac (NASDAQ:CVAC) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare CureVac to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Risk and Volatility

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, CureVac’s rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

17.3% of CureVac shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 2.1% of CureVac shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares CureVac and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
CureVac Competitors	-12,357.18%	-197.96%	-30.56%

Earnings & Valuation

This table compares CureVac and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CureVac	$70.74 million	$175.50 million	6.47
CureVac Competitors	$705.29 million	$10.71 million	-15.00

CureVac’s rivals have higher revenue, but lower earnings than CureVac. CureVac is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for CureVac and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1	0	0	0	1.00
CureVac Competitors	9829	15119	45431	1586	2.54

As a group, “Biotechnology” companies have a potential upside of 102.62%. Given CureVac’s rivals stronger consensus rating and higher probable upside, analysts plainly believe CureVac has less favorable growth aspects than its rivals.

Summary

CureVac rivals beat CureVac on 7 of the 13 factors compared.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.